LPX IO
Alternative Names: LPX-IOLatest Information Update: 21 Dec 2023
Price :
$50 *
At a glance
- Originator LAPIX Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Skin cancer
Most Recent Events
- 21 Dec 2023 Preclinical trials in Acute myeloid leukaemia in USA (PO) (Lapix Therapeutics Pipeline, December 2023)
- 21 Dec 2023 Preclinical trials in Skin cancer in USA (PO) (Lapix Therapeutics Pipeline, December 2023)
- 09 Apr 2023 Early research in Cancer in USA (PO) (Lapix Therapeutics Pipeline, April 2023)